Form 4: Avalo Therapeutics CFO Sells Shares
Insider Transaction (Form 4)
Christopher Ryan Sullivan, Chief Financial Officer of Avalo Therapeutics, Inc., sold 12,394 shares of common stock on September 16, 2026 for $16.33 per share.
Summary
- Option exercise/conversion: acquired 12,394 Common Stock at $9.88 ($122,453) on September 16, 2026; holds 52,294 after (Direct).
- Open-market sale: disposed of 12,394 Common Stock at $16.33 ($202,437) on September 16, 2026; holds 39,900 after (Direct).
- Option exercise/conversion: disposed of 12,394 Stock Option (Right to Buy) on September 16, 2026; holds 83,848 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $202,437 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Christopher Ryan Sullivan — Officer (Chief Financial Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-16 | Option exercise/conversion | Common Stock | 12,394 | $10 | $122.5K | 52,294 |
| 2026-09-16 | Open-market sale | Common Stock | 12,394 | $16 | $202.4K | 39,900 |
| 2026-09-16 | Option exercise/conversion | Stock Option (Right to Buy) | 12,394 | — | — | 83,848 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-16 | Option exercise/conversion (12,394 shares) |
| 2026-09-16 | Open-market sale (12,394 shares) |
| 2026-09-16 | Option exercise/conversion (12,394 shares) |
Keywords
insider transaction, Form 4, AVTX, Avalo Therapeutics, Inc., bearish, Christopher Ryan Sullivan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.